Cytrx Corp (NASDAQ:CYTR)

CAPS Rating: 2 out of 5

A biopharmaceutical research and development company engaged in developing human therapeutic products based primarily upon its small molecule molecular chaperone co-induction technology.

Results 1 - 20 of 35 : 1 2 Next »

Recs

0
Member Avatar feenix1944 (< 20) Submitted: 6/28/2014 12:34:12 PM : Outperform Start Price: $4.15 CYTR Score: -14.77

I've been backing the truck up to buy more CYTR on this recent weakness. I've drilled down pretty deep on the recent Stage IIb trial results and am fully convinced CYTR is a double bagger at the very least, and more likely a triple when the final results of the global trials are in. The CAPS Community seems to agree wholeheartedly, as well as a number of analysts.
One example from Wall St 24/7:
CytRx Corporation (NASDAQ:CYTR) on May 28 announced updated results from its ongoing multicenter, randomized, open-label global Phase 2b clinical trial investigating the efficacy and safety of aldoxorubicin compared with doxorubicin as first-line therapy in subjects with metastatic, locally advanced or unresectable soft tissue sarcomas (STS). The updated trial results demonstrated that aldoxorubicin significantly increases progression-free survival (PFS), PFS at 6 months, overall response rate (ORR) and tumor shrinkage, compared to doxorubicin, the current standard-of-care, as a first-line treatment in patients with STS. Analysts mean target price for CytRx Corporation (NASDAQ:CYTR) is $11.00 and On Friday shares its shares opened at $4.25 and trading at $4.14.CytRx Corporation (NASDAQ:CYTR) quarterly earnings growth is 134.80%.
Fellow Fools, I rest my case...
Feenix1944

Recs

0
Member Avatar AndrewGreenBull (99.20) Submitted: 2/28/2014 1:00:38 PM : Outperform Start Price: $5.46 CYTR Score: -40.89

$1 billion

Recs

1
Member Avatar csims2007 (< 20) Submitted: 10/24/2013 10:30:23 AM : Outperform Start Price: $2.65 CYTR Score: +22.13

just based on the value of the company it is a great buy at the current price.

Recs

3
Member Avatar zzlangerhans (99.69) Submitted: 7/17/2013 8:11:43 PM : Outperform Start Price: $2.50 CYTR Score: +25.76

With the discontinuation of tamibarotene development, CytRx now has all its chips on aldoxorubicin with results of a critical phase IIb trial in soft tissue sarcoma expected later this year. Does the company have enough juice to fuel a run up into data? It would seem that years of failure and loss of shareholder value would have demoralized the base, yet just a few days ago the stock briefly spiked more than 50% on rodent data for aldoxorubicin. So what's the real story here? I'll mark the stock with a green thumb and study it more closely for a real life position when the releases their next earnings PR.

Recs

0
Member Avatar GrandTheftHemi (< 20) Submitted: 11/30/2010 7:29:21 PM : Outperform Start Price: $7.42 CYTR Score: -116.51

Current clinicals , existing documented cases under compassionary use. Shall we be honest all Bio stocks come with risk but IMO this team is close...call it Speculation but IMO well timed...phase 1 target 2.35. Disclosure: You should always assume anytime someone talks about a stock that they are long or short...LONG here.

Recs

0
Member Avatar tootha1 (< 20) Submitted: 11/5/2010 12:26:37 PM : Outperform Start Price: $6.06 CYTR Score: -102.77

Lots of cash; great and experienced mgt; great pipeline

Recs

0
Member Avatar TheSwoonie (< 20) Submitted: 12/22/2007 10:29:40 AM : Outperform Start Price: $18.04 CYTR Score: -118.90

Good platform of trials, take over target.

Recs

0
Member Avatar tigerrusty (< 20) Submitted: 12/5/2007 1:29:32 PM : Outperform Start Price: $20.99 CYTR Score: -122.87

I think he stock will outperform because the company has three research platforms and a lot of new products that will come to market next year

Recs

0
Member Avatar willphipps (40.64) Submitted: 12/3/2007 5:24:39 PM : Outperform Start Price: $21.23 CYTR Score: -124.68

A buy at $3.30 or less...

Recs

0
Member Avatar fwwannabees (< 20) Submitted: 11/15/2007 5:13:40 PM : Outperform Start Price: $20.44 CYTR Score: -124.36

really new technology with a nobel prize winner on the board of directors

Recs

0
Member Avatar StockRakedotcom (< 20) Submitted: 10/8/2007 1:33:58 PM : Outperform Start Price: $22.40 CYTR Score: -117.95

Bought today.

Recs

0
Member Avatar drivdapmony4 (< 20) Submitted: 8/8/2007 4:02:02 PM : Outperform Start Price: $22.40 CYTR Score: -125.49

CYTR pipeline looks good and the recent spin off of RXi (RNA) that they will own 49% is in a very hot sector of biopharm.

Recs

0
Member Avatar yugp (< 20) Submitted: 8/5/2007 4:43:50 PM : Outperform Start Price: $18.72 CYTR Score: -125.50

This is a company with RNAi tech and the company will have several important announcements within several months.

Recs

0
Member Avatar Buhlzi (< 20) Submitted: 4/18/2007 9:10:39 AM : Outperform Start Price: $27.61 CYTR Score: -129.93

Nice accumulation and uptrend

Recs

0
Member Avatar idkblablabla (< 20) Submitted: 4/9/2007 7:06:59 PM : Outperform Start Price: $29.15 CYTR Score: -132.86

This stock may be near-term overpriced, but I believe its technology will lead to outsized returns over the long run, with intermittent large spikes in the stock price (upward as well as downward, but overall up). I am holding a small position from several weeks ago, from about 4.95. I will add to my position eventually.

Recs

2
Member Avatar edgarchisholm (< 20) Submitted: 3/12/2007 12:52:23 PM : Outperform Start Price: $24.73 CYTR Score: -135.15

CYTR has one of the top experts in the world on RNAI technology. He won the 2006 Nobel Prize in recognition of the potential for RNAI to create therapies for CANCER and other diseases that make them things of the past. CYTR's drug Arimolclomol has been given fast track status by the FDA. CYTR is using its proven delivery method which gives it a signigicant advantage in the market place.

This stock is at its begining and will easily be a ten bagger.

Recs

0
Member Avatar mhoepfin (45.42) Submitted: 3/7/2007 2:26:12 PM : Outperform Start Price: $25.77 CYTR Score: -136.21

Cutting edge research, excellent staff.

Recs

1
Member Avatar Arendt (< 20) Submitted: 2/26/2007 1:06:26 PM : Outperform Start Price: $27.92 CYTR Score: -132.34

Cytr has all the makings of a very good approach to medicine...just like the discovery of the vaccine...which was developed thru good overservations..like the earlier milkmaids who developed boils as result to exposures to diseased animals but did not develope the worse disease like small pox, etc. Careful and persistent researches and more advanced technology is now making it possible to go fast forward with this new medical approach to ever increasing spread of old and modern diseases. The beauty of this technique is that the developed interferones (RNAi) select only the malignant cells without harming the surrounding healthy cells. Knowledge coupled with advanced technology definitely will bring success to this new medical approach!

Recs

0
Member Avatar baronson23 (< 20) Submitted: 2/22/2007 5:31:26 PM : Outperform Start Price: $28.29 CYTR Score: -131.66

RNAi technology is on the innovative front edge. SIrna's purchase by Merck lends them credibility in a burgeoning space.

Recs

0
Member Avatar markacutshall (< 20) Submitted: 2/22/2007 9:34:26 AM : Outperform Start Price: $30.07 CYTR Score: -131.98

This company has money in the bank out the wazoo and 0 debt. How can anyone not see that there has to be growth there?

Results 1 - 20 of 35 : 1 2 Next »

Featured Broker Partners


Advertisement